NEOMatrix, the new commercial name of TK-NEO, is an R&D initiative of Takis, a Biotechnology Company with a scientific group with more than 10 years of experience in drug discovery, including the validation of new targets for the treatment of chronic viral diseases and cancer and to a number of IND/CSA filings in the areas of virology and oncology. The new frontier in Oncology is Cancer Immunotherapy, i.e. a therapy that stimulates the immune system to attack cancer cells, likewise vaccines can fight infectious diseases. Existing immunotherapies based on Immune Checkpoint Inhibitors (ICI) have been approved and commercialized with good results for many different cancers since 2011. However, the response rate of ICIs is still not so high and they still fail to achieve long-lasting responses in patients with metastatic disease, due to patient-specific mutations and intra-tumor heterogeneity (TH), i.e. treatment-resistant emerging variants in the same tumor typology. As a result, researchers are increasingly looking to attack neoantigens: protein fragments found only on cancer cells. Due to their unique nature, targeting them would allow a patient’s immune systems to find and attack cancer cells, while leaving healthy cells alone. NEOMatrix is a patent pending process for the production of patient specific DNA-based Neoantigen Cancer Vaccine (NCV) based on sequencing the genetic map of the tumor, identification of specific mutations that are present, production of the NCV and delivery to the patient in combination with ICIs. NEOMatrix, endowed with high poly-specificity and poly-functionality, was demonstrated in preclinical setting to be very efficient in preventing tumor growth, and has the potential to broaden the repertoire of immune responses against cancer, a feature that could be particularly relevant in the treatment of tumors with high heterogeneity, such as melanoma and lung cancer. The targeted procedure for production and delivery of NEOMatrix is based on a 6-week process, from sampling and sequencing the specific tumour DNA, synthesis of the right DNA sequence for the specific tumour, delivery through the DNA-EP device.